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Introduction
As the second leading cause of death and the leading cause of adult disability worldwide, stroke poses a serious threat to public health [1] . Ischaemic stroke and the associated inflammatory response, in particular, account for approximately 70-80% of neurological impairment associated with stroke. Activation of the immune system plays an important role in the pathophysiology of the brain injury that occurs after stroke, as demonstrated in both human and animal studies [2] . The extensive inflammatory response after stroke leads to severe brain injury and poor long-term outcomes [3] . Therefore, a better understanding of the inflammatory consequences of stroke can inform stroke management by focusing therapeutic strategies to reduce inflammation and to improve functional recovery.
Middle cerebral artery occlusion (MCAO) in mice is the classic animal model used for studying the consequences of ischaemia reperfusion and associated inflammation [4] . This model is often used to assess ischaemic stroke and is valuable in estimating the effects of treatment strategies [5] . T cells, particularly certain subtypes of T cells [T helper type 1 (Th1), Th2, Th17 and regulatory T cells (T reg cells)] play a critical role in inflammation resulting from ischaemic brain injury and are associated closely with outcomes following stroke [6] [7] [8] [9] [10] . Thus, one strategy to protect the brain following stroke-associated inflammation is to enhance the beneficial Th2 and T reg response, and the second is to prevent the destructive responses of Th1 and Th17.
Another therapeutic strategy is to target immunoproteasomes. Immunoproteasomes are specialized proteasomes expressed mainly in haematopoietic cells [11] , and are well known for processing proteins for major histocompatibility complex (MHC) class I presentation. Moreover, immunoproteasomal subunits have been shown to be up-regulated in a mouse model of ischaemic stroke [12, 13] , suggesting that they might be involved in the pathophysiology of the damage occurring after ischaemic stroke. Immunoproteasomes contain three major catalytic subunits: low molecular weight polypeptide 2 (LMP2) (b1i), multi-catalytic endopeptidase complex subunit (MECL) (b2i) and LMP7 (b5i). Increasing evidence indicates that immunoproteasomes are essential for T cell expansion and survival [14] , inflammatory cytokine production [15] [16] [17] and T cell differentiation [18] . Immunoproteasomes influence T cells through the nuclear factor kappa B (NF-jB) or signal transducer and activator of transcription (STAT) pathway and underlie the pathogenesis of multiple diseases. Blockade of the LMP7 subunit by PR-957 (also named ONX 0914), an immunoproteasome-specific inhibitor, strongly attenuates brain injury and suppresses activity of proinflammatory cytokines [15, 19] .
Apart from their role in experimental rheumatoid arthritis and inflammatory bowel disease, immunoproteasomes are also associated with degenerative neurological diseases of the central nervous system (CNS) [20, 21] , such as Alzheimer's disease. Immunoproteasomal subunits are up-regulated in a mouse model of ischaemic stroke [12, 13] , suggesting that they might be involved in the pathophysiology following ischaemic stroke. However, the molecular mechanisms mediating immunoproteasome activity during cerebral ischaemia are complicated.
Here, we conducted a detailed investigation of what role immunoproteasomes play during ischaemic stroke using the LMP7 inhibitor, PR-957. We hypothesize that this compound acts as an anti-inflammatory agent, whereby it modulates T cell responses in an experimental model of stroke. Our results point to a therapeutic opportunity to exploit the effects of this drug to mitigate brain injury after ischaemic stroke.
Materials and methods

Experimental animals
Adult male mice of C57BL/6 background (6-8 weeks old, 18-20 g) were obtained from Vital River Laboratories (Beijing, China). All the mice were housed in a temperature-and humidity-controlled room under 12-h light/12-h dark cycles. In our experiments, 50 mice were used for dose optimization of PR-957 treatment (Supporting information, Table S1 ). In addition, 324 adult male mice with a C57BL/6 background were assigned into three groups: sham-operated group, vehicle control group (MCAO 1 vehicle) and PR-957-treated group (MCAO 1 PR-957) (Supporting information, Table S2 ). During the experimental period, mice were provided food and water ad libitum and acclimated to the housing conditions for 1 week prior to the experiments. The number of animals needed for each experiment was calculated to be the minimum necessary to produce valid results. That calculation was the result of power analysis using G-Power software (G*Power version 3.1; Heinrich-Heine-Universitat D€ usseldorf, D€ usseldorf, Germany). To achieve a 5 0Á05 at b 5 0Á2 (power 80%) with a mean 20% standard deviation, results from sample size calculations show that the sample size should be at least six per group. All animal procedures were performed according to national regulations and were approved by the Animal Experiments Ethical Committee of Tianjin Medical University General Hospital. These are consistent with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines [22] .
Protocol for MCAO
Transient cerebral ischaemia was induced according to the methods reported by Longa et al. [4] . Briefly, this involved occlusion of the middle cerebral artery (MCA) using aseptic procedures. After anaesthetizing the mouse with 10% chloral hydrate [30 mg/kg, intraperitoneally (i.p.)], a ventral mid-line neck incision was made and the left common carotid artery (CCA), internal carotid artery (ICA) and the external carotid artery were exposed and isolated. A 0Á16-mm diameter monofilament (tip diameter, 0Á20 mm; Xinong, Beijing, China) was inserted into the ICA through the cut end of CCA and gently advanced 7-8 mm to block blood flow into the MCA. Sixty min after vessel occlusion, the monofilament was withdrawn to achieve ICA blood reperfusion. Regional cerebral blood flow (rCBF) corresponding to the perfusion territory of left MCA was monitored by a laser Doppler flowmeter (PF5010; Perimed AB, Beijing, China). Mice showed an 85% reduction of rCBF after occlusion was included in the following experiments. Body temperature was maintained by a heating pad. For the sham-operated group, mice were subjected to the same surgical protocol without insertion of monofilament. Buprenorphine (0Á03 mg/kg, i.p.) was given every 12 h within the first 24 h for pain management after surgery.
PR-957 promotes neuroprotection in MCAO mice
Treatment with PR-957
PR-957, purchased from Selleckchem (catalogue no. S7172; Shanghai, China), was dissolved in an aqueous mixture of 10% (w/v) sulphobutylether-b-cyclodextrin and 10 mM sodium citrate (pH 6). In a dose optimization study, mice were randomly administered a single i.p. injection of 5, 10, 20 or 30 mg/kg. We determined the optimum dose to be 20 mg/kg. This was based on results of 3 days of behavioural testing and infarct volume, which was measured 72 h after PR-957 treatment.
Three groups were composed of randomly assigned mice: a sham-operated group; a MCAO group (MCAO 1 vehicle); and a PR-957-treatment group (MCAO 1 PR-957). In the PR-957-treatment group, mice received a dose of 20 mg/kg PR-957; the sham-operated and MCAO groups of mice were given the same volume of vehicle [10% (w/v) sulphobutylether-b-cyclodextrin and 10 mM sodium citrate (pH 6)]. The corresponding solutions were injected i.p. into all mice at the beginning of ischaemia/ reperfusion (I/R); that is, after 60 min of MCAO.
Neurological assessment following MCAO
All three groups of mice -MCAO group (MCAO 1 vehicle), PR-957-treatment group (MCAO 1 PR-957) and sham-operated group (vehicle only) (n 5 10 each) -underwent neurobehavioural testing 24, 48 and 72 h after MCAO. These tests included the modified Neurological Severity Score (mNSS) [23] , the adhesive-removal test, the foot-fault test and the inclined plane test. For all testing, the observer was blinded to the experimental grouping. mNSS is a comprehensive evaluation method that assesses motor, sensory, reflex and balance function. It is graded on a scale of 0-18, with higher scores reflecting more severe deficits.
The adhesive-removal test [24] [25] [26] evaluates somatosensory and motor deficits. All mice were trained for 3 consecutive days before undergoing MCAO. After the mice were familiarized with the testing environment, the tester attached two adhesive paper dots gently to the distal region of each forelimb. The mice would naturally attempt to remove the paper dots from their limbs. After 3 days of training, all mice were able to remove both paper dots from their forelimbs. The elapsed time spent tearing off the paper dots from each forelimb was recorded for later statistical analysis. Three trials were performed using an intertrial interval of 5 min. The mice were then separated into different groups for other assessments.
In the foot-fault test [27] , a horizontal grid floor is used to assess locomotor function as the mouse crosses the surface. Briefly, paw misplacements (fault foots) were recorded for each run of the test (2 min). When the mouse's forelimb or hind limb fell into one of the grid openings, a foot fault was recorded. The number of foot faults for the three groups was evaluated statistically.
The inclined plane test was used to test the motor functions [28] . Mice were placed on a grooved, 1-mm-thick rubber surface and coaxed down an inclined plane platform. The incline of the platform was increased gradually until the mouse crept down from its starting position. The last incline position that the mouse maintained for 5 s without sliding down was recorded.
Infarct volume measurement
To assess the extent of anatomical damage after 60 min of vessel occlusion in our MCAO procedure, we perfused mice 24 or 72 h after MCAO surgery. Mice were anaesthetized with chloral hydrate (30 mg/kg, i.p.), and then perfused with 20 ml cold phosphate-buffered saline (PBS) (pH 7.4, 48C) through the left ventricle. The brains were removed rapidly for measurement of infarct volumes, as described previously [29] . Briefly, the brain was cut into five coronal blocks (2 mm thick), starting from the rostral tip of the cerebrum to the caudal tip. The five blocks were stained with 2% 2, 3, 5-tripenyltetrazolium chloride (TTC; Sigma, St Louis, MO, USA) at 378C for 20 min, followed by fixation in 4% paraformaldehyde at 48C for 1 h. After TTC staining, undamaged tissue appeared deep red, and infarcted tissue remained white. Image-Pro-Plus, version 6.0 image analysis software (Media Cybernetics, Washington, DC, USA) was used for determining the infarct volumes [30] . Infarct volumes are shown as a percentage of the volume of the corresponding areas in the whole brain to the infarct.
Immunofluorescent staining and analysis
Mice were anaesthetized with chloral hydrate (30 mg/kg, i.p.), and then perfused intraventricularly with PBS (pH 7.4, 48C). Brains were removed rapidly and then immersed in 30% sucrose with 4% paraformaldehyde overnight at 48C. After this whole-brain fixation and cryoprotection procedure, the brains were whole-frozen in liquid nitrogen. A standard cryostat (Leica Microsystems LM3050S, Shanghai, China) was used to slice coronal sections (8 lm), which were mounted on slides and stored at 2808C until staining. After 30 min at room temperature, the mounted sections were blocked in 3% bovine serum albumin (BSA) for 30 min at 378C. The sections were then incubated with primary antibodies overnight at 48C. Primary antibodies included rabbit anti-interleukin (IL)-17 (1 : 200; Abcam, Cambridge, UK) and mouse anti-CD4 (1 : 200; Santa Cruz Biotechnology, Dallas, TX, USA). Sections were next washed in cold PBS three times and incubated with secondary antibodies for 1 h at room temperature. Secondary antibodies included: Alexa Fluor V R 594-conjugated donkey anti-rabbit IgG (H 1 L) (1 : 1000; Thermo Fisher Scientific, Waltham, MA, USA) and Alexa Fluor V R 488-conjugated donkey anti-mouse IgG (H 1 L) (1 : 1000; Thermo Fisher Scientific). After five washes in cold PBS (10 min each), the sections were coverslipped, using fluoro-shield mounting medium containing 4 0 ,6-diamidino-2-phenylindole (DAPI) (Abcam) to counterstain cell nuclei. The sections were imaged using a fluorescence microscope (Nikon, Sendai, Ishinomaki, Japan). The number of positively stained CD4 cells and IL-17 cells were determined per mm 2 in the penumbra of the hemisphere ipsilateral to the MCAO from three randomly selected microscopic fields (3200 magnification), and the average results were used for analysis [31] .
Flow cytometric analysis [fluorescence activated cell sorter (FACS)]
Seventy-two h after MCAO, single-cell suspensions were prepared from the brains of mice from each group (six per group) for flow cytometric analysis. Natural killer (NK) cells (CD3 For Th1, Th2 and Th17 cell analysis, brain leucocytes were obtained as before and placed into 24-well plates (1 3 10 6 cells/well), where they were stimulated with 2 ml of cell activation cocktail (with brefeldin A) (Biolegend) for 4 h at 378C. Each vial of the cocktail contained 40Á5 mM phorbol-12-myristate 13-acetate, 669Á3 mM ionomycin and 2Á5 mg/ml brefeldin A in dimethylsulphoxide (DMSO). After stimulation, the cells were collected into 15-ml conical polypropylene centrifuge tubes and washed twice with PBS. The cells were transferred to polystyrene flow cytometry tubes, and then centrifuged at 400 g for 5 min. The resulting pellet was resuspended in 1% BSA and surfacestained with PerCP-conjugated anti-CD4 (1 : 200) antibody for 30 min at room temperature. After washing and fixation, cells were again washed twice with permeabilization buffer, and then stained with the following antibodies dissolved in permeabilization buffer for 30 min at room temperature: FITC-conjugated anti-IFN-g (1 : 100) for Th1 cells, PE-conjugated anti-IL-17 (1 : 100) for Th17 cells or FITC-conjugated anti-IL-4 (1 : 100) antibody for Th2 cells. Cells stained with isotype-control antibody were used to create background staining and to set analysis quadrants before calculating the percentage of positive cells. Flow cytometric data were acquired with a FACS Aria TM flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analysed with FlowJo software, version 7.6.1 (flowjo.com; Tree Star Inc., Ashland, OR, USA).
Western blot
Total protein was obtained from brain tissues with Trizol (Ambion, Waltham, MA, USA). Protein concentration was measured using a Protein Assay Kit (Beyotime, Hangzhou, China). Samples were separated on 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gels from 80 to 120 V, and then transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA) for 1Á5 h at 48C, 80 V. Membranes were blocked in 5% BSA solution for 1 h at room temperature, followed by incubation with primary antibody overnight at 48C. The membranes were then washed three times (10 min each), incubated with a horseradish peroxidase-coupled secondary antibody for 1 h, and washed again three times (10 min each). All incubations were performed in Tris-buffered saline (TBS buffer) with 0Á1% Tween-20. The primary antibodies were rabbit monoclonal antibody (mAb) phosphorylated signal transducer and activator of transcription 3 (pSTAT-3) (Tyr705) 
Enzyme-linked immunosorbent assay (ELISA) for determining cytokine profiles
Brain tissue was taken from ischaemic regions. Simultaneous quantitation of 12 cytokines (IL-1a, IL-1b, IL-2, IL-4, IL-6 , IL-10, IL-12, IL-17A, interferon (IFN)-g, tumour necrosis factor (TNF)-a, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) was accomplished using a multi-analyte ELISArray Kit (Qiagen, D€ usseldorf, Germany). Procedures followed the manufacturer's protocol. Each sample was analysed in triplicate from individual mouse brains (six mice per group), and results are expressed as mean optical density (OD) 6 standard error of the mean (s.e.m.).
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Total RNA was extracted from the ischaemic hemisphere using Trizol reagent (Ambion), according to the manufacturer's instructions. RNA concentration was quantified with ultraviolet spectrophotometry at 260/280 nm. Then, cDNA was transcribed from 5 lg of RNA with TransScript First-Strand cDNA Synthesis SuperMix (Transgen Biotech). PCR was performed on an Opticon 2 real-time PCR detection system (Bio-Rad) with SYBR gene PCR Master Mix (Roche, Basel, Switzerland). The primers are listed in Table  1 . Samples were run in duplicate at 958C for 10 min, then 40 cycles at 958C for 15 s, and finally at 608C for 1 min. Following automatic analysis with an ABI Stepone Plus instrument (Thermo Fisher), the results were calculated using the 2 -DDCt method. The expression levels of the mRNAs are reported as fold changes versus control (six mice per group).
Statistical analysis
All data are expressed as mean values 6 s.e.m. Statistical analyses were performed using Student's t-test for comparison of two groups and one-way analysis of variance (ANOVA), followed by the Bonferroni post-hoc test for multiple group comparisons (GraphPad Prism version 5.0; La Jolla, CA, USA); P < 0Á05 was considered significant.
Results
PR-957 reduces neurological deficits and infarct volume
Initially, mice subjected to MCAO received PR-957 at doses of 5, 10, 20 or 30 mg/kg administered as a single i.p. injection, and then the effect of each dose was assessed. Both the 20 and 30 mg/kg doses reduced the clinical score and infarct volumes significantly compared to the vehicle group ( Fig. 1a,b ; P < 0Á05). However, there were no significant differences in mNSS scores or infarct volumes between animals receiving the 20 mg/kg dose and of those receiving the 30 mg/kg dose. We determined that a PR-957 dose of 20 mg/kg was the optimal dose, as it produced the most significant improvement in neurobehavioural tests. The 20 mg/ kg dose also does not exceed the maximum tolerated dose of PR-957 [19] . Thus, all subsequent experiments were performed with 20 mg/kg PR-957 administered post-MCAO. After MCAO, reperfusion took place for 24, 48 or 72 h. Neurological function was then evaluated after each of these time-points. In the PR-957-treated group, neurological function scores 72 h after MCAO were better than those in the MCAO 1 vehicle group (Fig. 1c-f) . We observed large deficits in the MCAO 1 vehicle group compared to the shamoperated group, and PR-957 treatment reduced these deficits. Results from the mNSS tests exemplified this improvement ( Fig. 1c; P < 0Á05 at 48 h; P < 0Á01 at 72 h). The MCAO group had more foot-faults compared to the shamoperated group. When PR-957 was administered to MCAO mice, we observed markedly improved foot-fault performance ( Fig. 1d ; P < 0Á05 at 48 h; P < 0Á01 at 72 h). In the MCAO group, mice spent more time trying to remove the paper dots on their forelimbs than the mice in the shamoperated group. Administration of PR-957 shortened the average removal time ( Fig. 1e ; P < 0Á05 at 48 h; P < 0Á01 at 72 h). MCAO animals were impaired compared to shamoperated animals, and PR-957 prevented the motor function impairment seen after MCAO ( Fig. 1f; P < 0Á01) .
To evaluate the effects of PR-957 on brain injury after focal ischaemia and reperfusion in mice, we measured Table 1 . Primer sequences for quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR)
Genes
Primers (forward and reverse)
(F) CTCCAGAAGGCCCTCAGACTAC (R) GCTTTCCCTCCGCATTGACACAG RORgt (F) GTG GAC TTC GTT TGA GGA AAC (R) ACT TCC TCT GGT AGC TGG TCA C GAPDH 5 glyceraldehyde 3-phosphate dehydrogenase; IL 5 interleukin; TNF 5 tumour necrosis factor; RORgt 5 retinoic acid-related orphan receptor gamma T.
infarct volumes 24 and 72 h after MCAO. TTC staining clearly distinguished infarct areas from unaffected areas. As shown in Fig. 1 , treatment with PR-957 after ischaemic injury reduced the infarct volume significantly 24 h after MCAO ( Fig. 1g; P < 0Á05) . At 72 h, the MCAO 1 PR-957 group yielded nearly the same result ( Fig. 1g ; P < 0Á01). These results indicate that PR-957 treatment effectively attenuates the severity of neurological damage from brain ischaemia, and therefore appears to render some neuroprotection in MCAO mice.
PR-957 suppresses CD4
1 T cell infiltration and Th17 differentiation in brains of MCAO mice
With the following assays, we sought to understand the mechanism by which PR-957 protects against brain damage after MCAO. First, we performed flow cytometric analysis of cellular components from the brains of sham-operated mice, MCAO 1 vehicle mice and MCAO 1 PR-957 mice. The gating strategy for leucocytes appears in Fig. 2a (Fig. 2b-e) . While fewer CD4 1 T cells were present in the MCAO 1 PR-957 group ( Fig. 2b ; P < 0Á01), the numbers of CD8 1 T cells showed no obvious change (Fig. 2c) . No change in the counts of B cells (Fig. 2d ) or NK cells (Fig. 2e) was observed 72 h after MCAO among these three groups. Next, we determined to investigate the influences of PR-957 on CD4
1 T cell subpopulations in the brain 72 h after MCAO. Using the Th cell marker CD4 and IFN-g, Fig. 3b ) of MCAO 1 PR-957 mice showed decreased expression of Th17 ( Fig. 3a-c ; P < 0Á01). In summary, PR-957 suppresses CD4 T cell infiltration and Th17 differentiation after ischaemic stroke.
PR-957 reduces pSTAT-3 protein levels and retinoic acid-related orphan receptor gamma T (RORgt) mRNA levels in brains of MCAO mice
To determine whether PR-957 affects STAT-3 and RORgt, two important transcriptional regulators of Th17 cell differentiation, we analysed STAT-3 and RORgt expression in the brains of mice 72 h after MCAO. We measured pSTAT-3 (Tyr705) protein levels and RORgt mRNA levels via Western blotting (Fig. 4a-c ) and qRT-PCR (Fig. 4d) , respectively. Western blotting revealed that the MCAO 1 PR-957 group expressed less pSTAT-3 (Tyr705) compared to the MCAO 1 vehicle group ( Fig. 4b ; P < 0Á05). However, STAT-3 protein level did not differ significantly throughout these groups (Fig. 4c) . Furthermore, RORgt mRNA expression decreased significantly in the brains of MCAO 1 PR-957 mice compared to the brains of MCAO 1 vehicle mice ( Fig. 4d ; P < 0Á05). Overall, PR-957 reduced the phosphorylation of STAT-3 at the protein level, causing a reduction of RORgt at the transcriptional level after MCAO.
PR-957 moderates the inflammatory milieu in postischaemic brain
We studied the cytokine profiles in the mouse brain by ELISA and qRT-PCR. We assessed the levels of the following inflammatory cytokines: IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17A, IFN-g, TNF-a, G-CSF and GM-CSF. IL-1b, IL-6, IL-12, IL-17A, IFN-g and TNF-a were reduced significantly in the MCAO 1 PR-957 group compared to those in the MCAO 1 vehicle group ( Fig. 5a ; P < 0Á05 for IL-1b, IL-6, IL-12, IL-17A and IFN-g; P < 0Á01 for TNFa). However, protein levels of IL-1a, IL-2, IL-4, IL-10, G-CSF and GM-CSF were not significantly different between the MCAO 1 vehicle group and the MCAO 1 PR-957 group. We also studied the cytokine profiles in the mouse brain by qRT-PCR. The mRNA levels of IL-1b, IL-6, IL-12, IL-17, IL-23 and TNF-a were decreased in the MCAO 1 PR-957 group compared to those in the MCAO 1 vehicle group ( Fig. 5b-g ; P < 0Á05). These results suggest that PR-957 could alleviate inflammatory milieu after ischaemic stroke. It appears that PR-957 mediated the anti-inflammatory effect after experimentally induced stroke and reperfusion. Presumably, therefore, PR-957 is involved in regulating the balance between proinflammatory and anti-inflammatory Th cells in MCAO mice via inhibiting the STAT-3/RORgt pathway (Fig. 6 ).
Discussion
We hypothesized that PR-957, a selective inhibitor of the immunoproteasome subunit LMP7 and an antiinflammatory agent, might mitigate inflammationassociated neuronal damage after ischaemic stroke. The results of the present study support the hypothesis that PR-957 is neuroprotective in MCAO mice. Our experiments with a classic animal model of I/R injury, caused by transient MCAO, demonstrate strongly that PR-957 is capable of reducing infarct volume, diminishing the associated neurological deficits, and attenuating the inflammatory reaction. The neuroprotective effect of PR-957 aligns well with our observation in the present study that lymphocyte concentration and Th17 cell accumulation were inhibited substantially in brains undergoing such injury and with the suppression of proinflammatory cytokines. PR-957 treatment in MCAO mice inhibited the STAT-3 signalling pathway, which corresponded with decreased RORgt levels. This, in turn, contributed to a decline of Th17 cells in the brain. Moreover, protein and mRNA levels of proinflammatory cytokines were down-regulated significantly in the brains of MCAO mice after PR-957 treatment.
Previous studies have emphasized that T lymphocytemediated inflammation plays a central role during ischaemic brain injury. Following acute ischaemic stroke, T lymphocytes become activated, infiltrate through the brain-blood barrier and accumulate in ischaemic core tissue [6] . T lymphocytes begin to infiltrate into this core 24 h after ischaemic stroke and reach their peak 3 days after onset [32, 33] . After ischaemic stroke an inflammatory cascade breaks out, in which T cells and their subpopulations take part in inflammation-mediated brain injury [7, 34] . Prior research shows that IL-17 plays a more important role in cerebral I/R injury than IFN-g [35] . IL-17 is a proinflammatory cytokine produced by Th17 cells and gdT cells. The gdT cells infiltrate the infarct boundary zones in an early phase after ischaemic stroke, and then release a large amount of IL-17. After a few days, Th17 cells are the chief source of IL-17 [36] . Also, IL-17A secreted by Th17 cells may aggravate brain injury after ischaemic stroke. IL-23 released by macrophages may also stimulate the production of IL-17 [37, 38] . Besides this response, increased levels of TNF-a and IL-1 can also stimulate IL-17 secretion [39] .
In the present study, improvements of MCAO mice treated with PR-957 were associated with significantly fewer Th17 cells in their brains compared to their vehicletreated counterparts. PR-957 also reduced mRNA expression of IL-1b, IL-6, TNF-a, IL-12, IL-17 and IL-23 in the brains of MCAO mice. ELISAs of brain supernatants from MCAO mice showed the same downward trend in proinflammatory cytokines. Our results suggest that the PR-957-associated improvement of the inflammatory environment after MCAO was the basis for the neuroprotective effect documented here.
Considerable evidence indicates that CD4 1 CD25
1
FoxP3
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T cells play a key role in moderating immune responses under physiological and pathological conditions in the CNS through anti-inflammatory cytokines [7, 40] . However, our PR-957-treatment group did not differ in T reg cell counts compared to the vehicle-treated control group (MCAO 1 vehicle) at 72 h post-MCAO reperfusion. Additionally, studies show that LMP7 inhibition is effective in preventing differentiation of naive Th cells to polarized Th1 cells and Th17 cells in vivo and vitro [16] [17] [18] [19] . Our flow cytometric results show that Th17 expression is reduced in MCAO brains from mice treated with PR-957 compared to the control group (MCAO 1 vehicle). Similarly, double-immunofluorescence staining of brain tissue from mice treated with PR-957 also showed a reduction of IL-17 expression compared to the control group. Nevertheless, the number of Th1 or Th2 cells was not statistically different in the latter experiment, similar to the flow cytometric results. In a study of experimental autoimmune encephalomyelitis in which PR-957 was administered, differentiation to Th17 or Th1 cells was impaired [16] . This result is at variance with the present study. One possible reason for this may be related to the different animal models used in the two studies and/or differences in technical methods. Other research exploring the mechanism of PR-957's involvement in the control of T cell expansion [18, 19] proposed initially that LMP7 is a regulator of cytokine production accompanying NF-jB-independent pathways [19] .
Additionally, the STAT-3 pathway has been studied in a model of colitis, which is relevant to Th17 differentiation. This report posited that the down-regulation by PR-957 of RORgt mRNA production is a factor in Th17 differentiation, due most probably to reduced phosphorylation of STAT-3 [18] . Although the molecular mechanism governing Th17 cell differentiation is somewhat imprecise, IL-6 and IL-23 may affect Th17 cell differentiation synergistically [41, 42] . Furthermore, STAT-3 may serve as a selective STAT protein in cytokine-mediated Th17 cell polarization in the presence of IL-6 and IL-23 [43] . In the present study, PR-957 not only down-regulated the expression of IL-6 and IL-23, but also decreased STAT-3 phosphorylation in naive CD4
1 T cells. These changes might result from a reduction of RORgt, the key transcription factor for Th17 cell differentiation and IL-17 production. As shown in Fig.  6 , the reduction of STAT-3 phosphorylation may suppress Th17 cell differentiation directly, thereby supporting the participation of PR-957 in the STAT-3 pathway. In our In accord with a demonstration that inhibition of LMP2 and LMP7 significantly alleviates inflammatory reactions and protects against focal cerebral ischaemia injury in MCAO rats [13] , our present study demonstrated that PR-957 is a selective immunoproteasome inhibitor in a murine model of MCAO. Our results also support the idea that inhibition of LMP7 provides neuroprotection after MCAO. However, in contrast with that former study, which involved the regulation of NF-jB activation in ischaemic stroke, we provide new evidence that PR-957 inhibits the STAT-3 pathway and, thereby, plays a central role in regulating the balance between proinflammatory and anti-inflammatory Th cells in MCAO mice.
In summary, PR-957 exerted a neuroprotective effect against ischaemic stroke through modulating Th17 differentiation and regulating the cytokine profile of immune responses in the brain. This demonstration that PR-957 attenuates inflammation in MCAO mice might offer a strategy for targeting the immune system with therapeutic intervention after stroke. 
Supporting information
Additional Supporting information may be found in the online version of this article at the publisher's web-site: Table S1 . Numbers of mice used to for dose optimization of PR-957 treatment. Table S2 . Numbers of mice used in the formal experiments.
